Patent intelligence · US
US 9149468
Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid
Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]…
Patent details — US 9149468
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 6, 2015
- Expiration
- Oct 1, 2035
- Applicant
- TEVA GmbH
- Claims
- 20
- CPC classes
- A61K, A61K31/196, A61K31/44, A61P
Quick answer
US 9149468 (Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid) is held by TEVA GmbH. Status: granted. Granted Oct 6, 2015. Expires Oct 1, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA GmbH
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/196, A61K31/44, A61P, A61P25/04, A61P29/00
More from TEVA GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 9149468?
US 9149468 (Multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid) is held by TEVA GmbH. Status: granted. Granted Oct 6, 2015. Expires Oct 1, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9149468?
TEVA GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 9149468 expire?
Our index shows an expiration date of Oct 1, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.